Aptabio Receives Approval for IND Application to Conduct Phase 2 Clinical Trial of APX-115 for Diabetic Nephropathy in Europe
[Asia Economy Reporter Oh Ju-yeon] Aptabio announced on the 12th that it has received approval for the Investigational New Drug (IND) application for the Phase 2 clinical trial of APX-115, a treatment for diabetic nephropathy, in Europe. The company stated, "Currently, there are no drugs approved specifically for diabetic nephropathy, and ARB/ACE class antihypertensive drugs are only used as symptomatic treatments, so there is a significant demand for the development of new treatments for diabetic nephropathy." They added, "APX-115 exerts therapeutic effects on diabetic nephropathy by antagonizing the NOX enzyme, which is the fundamental cause of diabetic nephropathy, thereby regulating oxidative stress. Safety in humans was confirmed in the European Phase 1 clinical trial, and after conducting this clinical study and completing development, we plan to proceed to global Phase 3 clinical trials."
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051414165763158_1778735817.jpg)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Trump Puts Iran Strike on Hold One Day Before Attack... "Full-Scale Offensive If Talks Fail"
- [New York Stock Market] Mixed Close Amid Tech Stock Declines and Stalled Ceasefire Talks
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
